The latest moves, appointments and personnel changes among wealth management and related organisations in the UK, the rest of Europe, the Middle East, Africa and select international locations.

Canaccord Genuity Wealth Management
UK independent wealth management firm Canaccord Genuity Wealth Management in the UK and Crown Dependencies (Canaccord Wealth), has appointed investment director, Paul Fielding to join its Birmingham team.

Fielding, who has more than 28 years’ experience in the investment industry, specialises in discretionary investment management for private clients, trusts, pension schemes and charities. He manages portfolios that include a range of investments such as equities, fixed interest securities, collective investments and structured products. Fielding was previously at RBC Brewin Dolphin where he worked for 23 years.

Fielding’s appointment is the latest senior hire Canaccord Wealth has made across its regional network, reflecting the firm’s burgeoning investment management presence in Birmingham and other key regions throughout the UK.

“We believe Paul will make an excellent addition to the Birmingham team, along with senior investment professional Roger Sedgwick who also recently joined. Paul’s experience and depth of expertise perfectly complements the investment management and wealth planning capabilities Canaccord Wealth has in the Midlands.” Duncan Stratford, managing director of Canaccord Wealth, said. “Senior hires, such as Paul’s, are key to advancing our ambition to provide the best integrated wealth management services for our clients throughout the UK.”

AAX Biotech
AAX Biotech, a Swedish startup biotech company aiming to solve unmet needs in developing next-generation antibody therapeutics, has appointed Patrik Strömberg to join its board of directors.

Hiring Strömberg marks an important step in AAX Biotech's strategic expansion as the company continues to build impactful collaborations with biotech and pharmaceutical partners, the firm said in a statement.

His “substantial experience” comes from key roles working at pharmaceutical companies including AstraZeneca and Biovitrum/Sobi. Since 2021, he has served as the CEO of AnaCardio. He holds a PhD in biochemistry from Karolinska Institutet and an MBA from Stockholm University.

"Patrik Strömberg's comprehensive knowledge in both scientific and business aspects of the pharmaceutical industry makes him an invaluable addition to the board," Maria Lisa Knudsen, CEO of AAX Biotech, said. "His insights and leadership will be instrumental in accelerating our growth, enhancing our technological capabilities and solidifying our position in the global market."